Article
Oncology
Cedric Pobel, Edouard Auclin, Diego Teyssonneau, Brigitte Laguerre, Mathilde Cancel, Elouen Boughalem, Johanna Noel, Pierre Emmanuel Brachet, Denis Maillet, Philippe Barthelemy, Carole Helissey, Constance Thibault, Stephane Oudard
Summary: Cabazitaxel multiple rechallenges can be a treatment option in heavily pretreated patients with metastatic castration-resistant prostate cancer, with efficacy and manageable toxicity for those who had a good initial response to cabazitaxel.
Editorial Material
Oncology
Simon Van Wambeke, Francisco Emilio Vera-Badillo, Bishal Gyawali
Summary: This article takes a serious look at the standards for a control arm in metastatic castration-resistant prostate cancer, questioning whether ARTA after ARTA is good enough.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Urology & Nephrology
Di Maria Jiang, Nazanin Fallah-Rad, Roy Lee, Pamela Ng, Alan D. Smith, Aaron R. Hansen, Anthony M. Joshua, Jaclyn Beca, Srikala S. Sridhar
Summary: By cohorting patients receiving cabazitaxel on the same weekday, drug wastage and associated costs were significantly reduced, leading to a cost saving of $394 536 CAD (21.1%) over a 3-year period. Similar strategies could potentially be implemented to mitigate the financial burden associated with drug wastage for cabazitaxel and other oncology drugs.
Article
Urology & Nephrology
Kristine Kreis, Dirk Horenkamp-Sonntag, Udo Schneider, Jan Zeidler, Gerd Glaeske, Lothar Weissbach
Summary: This study examined real-world haematological toxicity, overall survival, and treatment characteristics of docetaxel and cabazitaxel chemotherapy in mCRPC patients. The findings suggest that cabazitaxel treatment poses higher risk of haematological toxicities and shorter survival time, emphasizing the importance of strict indications when using cabazitaxel in mCRPC patients.
Article
Medicine, General & Internal
Giorgia Gurioli, Vincenza Conteduca, Nicole Brighi, Emanuela Scarpi, Umberto Basso, Giuseppe Fornarini, Alessandra Mosca, Maurizio Nicodemo, Giuseppe Luigi Banna, Cristian Lolli, Giuseppe Schepisi, Giorgia Ravaglia, Isabella Bondi, Paola Ulivi, Ugo De Giorgi
Summary: This study evaluated the prognostic role of CTC gene expression in cabazitaxel-treated mCRPC patients and its association with plasma AR copy number. The results showed that CTC gene expression was significantly associated with overall survival and disease progression. AR-V7 was identified as an important prognostic biomarker, and patients with AR-V7 positivity had poorer outcomes with lower dose cabazitaxel treatment.
Article
Pharmacology & Pharmacy
Nityam Rathi, Taylor Ryan McFarland, Roberto Nussenzveig, Neeraj Agarwal, Umang Swami
Summary: Immunotherapies have shown success in treating multiple cancer types, but have faced challenges in prostate cancer. The immune evasion in prostate cancer is attributed to intrinsic tumor factors, immunosuppressive tumor microenvironment, and host factors. Researchers are exploring ways to transform prostate cancer from a 'cold' tumor to a 'hot' tumor through various approaches, including immune checkpoint inhibitors and other upcoming immunotherapies.
Article
Multidisciplinary Sciences
Keitaro Watanabe, Takeo Kosaka, Hiroshi Hongo, Mototsugu Oya
Summary: The study found that the combination of prophylactic antibiotics during cabazitaxel therapy can significantly reduce the occurrence of febrile neutropenia.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Cedric Pobel, Edouard Auclin, Adrien Procureur, Alice Clement-Zhao, Audrey Simonaggio, Nicolas Delanoy, Yann-Alexandre Vano, Constance Thibault, Stephane Oudard
Summary: Cabazitaxel is a standard second-line chemotherapy for metastatic castration-resistant prostate cancer patients who have been treated with docetaxel. However, its toxicity to white blood cells poses a risk of infectious complications, particularly in frail elderly patients. Use of prophylactic white blood cell-stimulating agents is crucial for maximizing the benefit-risk ratio, and alternative schedules show promise especially for frail patients.
Article
Oncology
Mihaela Aldea, Laurent Lam, Emeline Orillard, Casilda Llacer Perez, Mathilde Saint-Ghislain, Gwenaelle Gravis, Aude Flechon, Guilhem Roubaud, Philippe Barthelemy, Francesco Ricci, Frank Priou, Zoe Neviere, Mathilde Beaufils, Brigitte Laguerre, Anne-Claire Hardy, Carole Helissey, Raffaele Ratta, Delphine Borchiellini, Cedric Pobel, Florence Joly, Elena Castro, Antoine Thiery-Vuillemin, Giulia Baciarello, Karim Fizazi
Summary: The study suggests that cabazitaxel is effective in patients with mCRPC regardless of their DNA damage repair (DDR) status, although its efficacy may be lower in men pretreated with PARPi.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Filippos Koinis, Zafeiris Zafeiriou, Ippokratis Messaritakis, Panagiotis Katsaounis, Anna Koumarianou, Emmanouil Kontopodis, Evangelia Chantzara, Chrissovalantis Aidarinis, Alexandros Lazarou, George Christodoulopoulos, Christos Emmanouilides, Dora Hatzidaki, Galatea Kallergi, Vassilis Georgoulias, Athanasios Kotsakis
Summary: This study assessed the clinical relevance of monitoring circulating tumor cells (CTCs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel. The study demonstrated that CTC counts at baseline and after the first treatment cycle retain their prognostic significance.
Article
Oncology
Aurelius Omlin, Richard Cathomas, Gunhild von Amsberg, Christoph Reuter, Susan Feyerabend, Wolfgang Loidl, Martin Boegemann, Anja Lorch, Axel Heidenreich, Igor Tsaur, Julian Larcher-Senn, Stefan A. J. Buck, Ron H. J. Mathijssen, Ulrich Jaehde, Silke Gillessen, Markus Joerger
Summary: This study compares the efficacy of cabazitaxel at different doses in patients with metastatic castration-resistant prostate cancer (mCRPC) and finds that individual dose adjustments of cabazitaxel can improve clinical feasibility and survival outcome in patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Chemistry, Medicinal
Zhen Qu, Yuning Ren, Hongyu Shen, Huihui Wang, Lijie Shi, Deyong Tong
Summary: A novel nano-system targeting prostate cancer was developed with high drug loading efficiency and antitumor effect, showing potential as a promising therapy for prostate cancer.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Urology & Nephrology
Cora N. Sternberg, Daniel Castellano, Johann de Bono, Karim Fizazi, Bertrand Tombal, Christian Wuelfing, Gero Kramer, Jean-Christophe Eymard, Aristotelis Bamias, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Asgerdur Sverrisdottir, Christine Theodore, Susan Feyerabend, Carole Helissey, Elizabeth M. Poole, Ayse Ozatilgan, Christine Geffriaud-Ricouard, Ronald de Wit
Summary: In the study of metastatic castration-resistant prostate cancer patients, older and younger patients receiving cabazitaxel showed better results in terms of radiographic progression-free survival compared to abiraterone/enzalutamide.
Article
Oncology
Charlien Berghen, Steven Joniau, Piet Ost, Kenneth Poels, Wouter Everaerts, Karel Decaestecker, Karin Haustermans, Gaetan Devos, Gert De Meerleer
Summary: In mCRPC patients, targeting a limited number of progressive lesions with surgery or high-dose radiation therapy while maintaining ongoing systemic treatment for other metastases significantly delayed the initiation of next-line systemic treatment. This approach could be a promising strategy in managing oligoprogressive mCRPC.
EUROPEAN UROLOGY ONCOLOGY
(2021)
Article
Medicine, General & Internal
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian D. Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie K. Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun A. Azad, Shakher Ramdave, Andrew D. Redfern, William Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Y. Zhang, Margaret M. McJannett, Martin R. Stockler, John A. Violet, Scott G. Williams, Andrew J. Martin, Ian D. Davis
Summary: [Lu-177]Lu-PSMA-617 showed a higher PSA response and fewer grade 3-4 adverse events compared to cabazitaxel in men with metastatic castration-resistant prostate cancer.
Article
Urology & Nephrology
J. Alberto Nakauma-Gonzalez, Maud Rijnders, Job van Riet, Michiel S. van der Heijden, Jens Voortman, Edwin Cuppen, Niven Mehra, Sandra van Wilpe, Sjoukje F. Oosting, L. Lucia Rijstenberg, Hans M. Westgeest, Ellen C. Zwarthoff, Ronald de Wit, Astrid A. M. van der Veldt, Harmen J. G. van de Werken, Martijn P. J. Lolkema, Joost L. Boormans
Summary: This study analyzed the molecular and genetic features of metastatic urothelial carcinoma (mUC) and identified different genomic and transcriptomic subtypes, providing potential therapeutic options for individualized treatment. The findings have significant clinical implications.
Article
Oncology
Sandra van Wilpe, Shabaz Sultan, Mark A. J. Gorris, Diederik M. Somford, Heidi V. N. Kusters-Vandevelde, Rutger H. T. Koornstra, Winald R. Gerritsen, Michiel Simons, Antoine G. van der Heijden, I. Jolanda M. de Vries, Niven Mehra
Summary: The aim of this study was to improve our understanding of the immune-modulating effects of neoadjuvant cisplatin-based chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC) patients. We found a decrease in intratumoral CD3(+) T cell density following NAC in MIBC patients with an early recurrence.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Maarten J. van der Doelen, Irma M. Oving, Dirk N. J. Wyndaele, Jean-Paul van Basten, Frederiek Terheggen, Addy C. M. van de Luijtgaarden, Wim J. G. Oyen, W. Dick van Schelven, Franchette van den Berkmortel, Niven Mehra, Marcel J. R. Janssen, Judith B. Prins, Winald R. Gerritsen, Jose A. E. Custers, Inge M. van Oort
Summary: This study evaluated the health-related quality of life, psychological distress, and fatigue in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223. The study found that patients who discontinued radium-223 therapy had worse HR-QoL, psychological distress, and fatigue at baseline and more frequent deterioration over time compared to patients who completed therapy.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
Gijs P. A. van den Bergh, Malou C. P. Kuppen, Hans M. Westgeest, Niven Mehra, Winald R. Gerritsen, Katja K. H. Aben, Inge M. van Oort, Reindert J. A. van Moorselaar, Diederik M. Somford, Alfonsus J. M. van den Eertwegh, Andre M. Bergman, Alphonsus C. M. van den Bergh, Carin A. Uyl-de Groot
Summary: This real-world population study investigates the incidence and treatment of visceral metastases (VMs) in castration-resistant prostate cancer (CRPC) patients and their survival. The study found that the location of VMs impacts patients' survival and despite an increase in radiological staging, many patients were not screened for VMs at the start of systemic treatment. Routine staging of CRPC patients is necessary.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Biochemistry & Molecular Biology
Jeroen van Dorp, Christodoulos Pipinikas, Britt B. M. Suelmann, Niven Mehra, Nick van Dijk, Giovanni Marsico, Maurits L. van Montfoort, Sophie Hackinger, Linde M. Braaf, Tauanne Amarante, Charlaine van Steenis, Kirsten McLay, Antonios Daletzakis, Daan van den Broek, Maaike W. van de Kamp, Kees Hendricksen, Jeantine M. de Feijter, Thierry N. Boellaard, Richard P. Meijer, Toine G. van der Heijden, Nitzan Rosenfeld, Bas W. G. van Rhijn, Greg Jones, Michiel S. van der Heijden
Summary: Cohort 1 of the phase 1B NABUCCO trial showed high pCR rates with preoperative ipilimumab plus nivolumab in stage III UC. In cohort 2, dose adjustment was aimed to optimize responses. Absence of ctDNA in plasma can predict PFS in stage III UC patients treated with high-dose ipilimumab plus nivolumab.
Article
Radiology, Nuclear Medicine & Medical Imaging
Steffie M. B. Peters, Maaike C. T. Mink, Bastiaan M. Prive, Maarten de Bakker, Frank de Lange, Constantijn H. J. Muselaers, Niven Mehra, J. Alfred Witjes, Martin Gotthardt, James Nagarajah, Mark W. Konijnenberg
Summary: This study aims to develop a clinically implementable protocol to determine the absorbed dose in organs and tumor lesions after [Lu-177]Lu-PSMA-617 therapy. Accurate lesion dosimetry can be performed using a one- or two-time point protocol, while dosimetry based on planar scans is not accurate.
Article
Oncology
Amina Banda, Bastiaan M. Prive, Youssra Allach, Maike J. M. Uijen, Steffie M. B. Peters, Cato C. Loeff, Martin Gotthardt, Constantijn H. J. Muselaers, J. Alfred Witjes, Inge M. van Oort, J. P. Michiel Sedelaar, Harm Westdorp, Niven Mehra, Fadi Khreish, Samer Ezziddin, Amir Sabet, Michael C. Kreissl, Thomas Winkens, Philipp Seifert, Marcel J. R. Janssen, Willemijn A. M. van Gemert, James Nagarajah
Summary: Prostate-specific membrane antigen-directed radioligand therapy (PSMA-RLT) is a novel treatment option for castration-resistant prostate cancer. This study investigated the safety and efficacy of two PSMA-RLT schemes in early-stage metastatic prostate cancer patients. The treatment was found to be safe with limited side effects and showed promising efficacy.
Article
Biochemistry & Molecular Biology
Levi Groen, Iris Kloots, David Englert, Kelly Seto, Lana Estafanos, Paul Smith, Gerald W. Verhaegh, Niven Mehra, Jack A. Schalken
Summary: The clinical utility of circulating tumor cells (CTC) as a non-invasive multipurpose biomarker is well recognized. The earliest methods for enriching CTCs relied on antibody-based positive selection, but it has limitations in capturing the heterogeneity of cancer. This study used the recently FDA-approved Parsortix (R) technology to enrich CTCs from prostate cancer patients and found that targeted CTC transcriptome profiling may be predictive of therapy response.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin, Jae Lyun Lee, Niven Mehra, Ray McDermott, Nuria Sala-Gonzalez, Peter C. Fong, Richard Greil, Margitta Retz, Juan Pablo Sade, Patricio Yanez, Yi-Hsiu Huang, Stephen D. Begbie, Rustem Airatovich Gafanov, Maria De Santis, Eli Rosenbaum, Michael P. Kolinsky, Felipe Rey, Kun-Yuan Chiu, Guilhem Roubaud, Gero Kramer, Makoto Sumitomo, Francesco Massari, Hiroyoshi Suzuki, Ping Qiu, Jinchun Zhang, Jeri Kim, Christian H. Poehlein, Evan Y. Yu
Summary: This study evaluated the efficacy of pembrolizumab plus olaparib compared to a next-generation hormonal agent (NHA) for heavily pretreated mCRPC patients. The results showed that pembrolizumab plus olaparib did not significantly improve rPFS or OS. The study was stopped for futility and no new safety signals were observed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Jeroen H. A. Creemers, Ankur Ankan, Kit C. B. Roes, Gijs Schroeder, Niven Mehra, Carl G. Figdor, I. Jolanda M. de Vries, Johannes Textor
Summary: Late-stage cancer immunotherapy trials often result in unique survival curve shapes, and it is crucial to anticipate and adjust the trial design accordingly. This study used simulated trials based on three mathematical models to investigate the survival curve shapes associated with immunotherapies. By simulating different scenarios, the authors demonstrated how trial design choices can be scrutinized and potential pitfalls can be identified. They also provided web-based implementations of their simulation models to facilitate their use by biomedical researchers, doctors, and trialists.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Peter H. J. Slootbeek, Iris S. H. Kloots, Inge M. van Oort, Leonie I. Kroeze, Jack A. Schalken, Haiko J. Bloemendal, Niven Mehra
Summary: Patients with mCRPC and HRRm can benefit from both PlCh and PARPi, with PlCh inducing less cross-resistance. The order of agents in treatment influenced the PFS, with shorter PFS after PARPi when administered second and shorter PFS after PlCh when administered first. More than 40% of the patients were sensitive to a subsequent HRR-targeting agent. Understanding resistance mechanisms is crucial for determining optimal treatment sequence in HRRm mCRPC patients.
Article
Oncology
Peter H. J. Slootbeek, Joanneke K. Overbeek, Marjolijn J. L. Ligtenberg, Nielka P. van Erp, Niven Mehra
Summary: PARP inhibitors have shown great potential in the treatment of metastatic castration-resistant prostate cancer, with superior responses observed in patients with BRCA1 or BRCA2 gene mutations. Combination therapy with androgen receptor signaling inhibitors can prolong progression-free survival in HRRm patients, but has limited efficacy in the non-HRRm subgroup.
Review
Pharmacology & Pharmacy
Eva Podgorsek, Niven Mehra, Inge M. M. van Oort, Diederik M. M. Somford, Emmy Boerrigter, Nielka P. P. van Erp
Summary: Darolutamide is a next-generation androgen receptor signaling inhibitor (ARSI) approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone sensitive prostate cancer (mHSPC). It has the potential to be used in other stages of prostate cancer (PC) as well. Pharmacokinetic properties and patient characteristics can help physicians decide the choice of ARSIs.
CLINICAL PHARMACOKINETICS
(2023)
Review
Medical Laboratory Technology
Peter H. J. Slootbeek, Sofie H. Tolmeijer, Niven Mehra, Jack A. Schalken
Summary: The treatment of metastatic castration-resistant prostate cancer has been transformed by precision oncology, aiming to match targeted therapies with tumor genotypes through ctDNA sequencing to monitor treatment response and resistance mechanisms for improved outcomes.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
(2023)
Article
Urology & Nephrology
Niven Mehra, Iris Kloots, Michiel Vlaming, Shafak Aluwini, Els Dewulf, Daniela E. Oprea-Lager, Henk van der Poel, Herman Stoevelaar, Derya Yakar, Chris H. Bangma, Elise Bekers, Roderick van den Bergh, Andries M. Bergman, Franchette van den Berkmortel, Steve Boudewijns, Winand N. M. Dinjens, Jurgen Futterer, Tom van der Hulle, Guido Jenster, Leonie I. Kroeze, Michel van Kruchten, Geert van Leenders, Pim J. van Leeuwen, Wendy W. J. de Leng, R. Jeroen A. van Moorselaar, Walter Noordzij, Rogier A. Oldenburg, Inge M. van Oort, Irma Oving, Jack A. Schalken, Ivo G. Schoots, Ed Schuuring, Robert J. Smeenk, Ben G. L. Vanneste, Erik Vegt, Andre N. Vis, Kim de Vries, Peter-Paul M. Willemse, Maurits Wondergem, Margreet Ausems
Summary: A group of Dutch specialists discussed the use of germline and tumour genetic testing in prostate cancer (PCa) patients, indication of these tests (which patients and when), and impact of these tests on the management and treatment of PCa.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)
